Surgeon, Department of Podiatric Surgery, Kaiser Permanente Oakland Medical Center, Oakland, CA.
Senior Data Consultant, Division of Research, Kaiser Permanente Northern California, Oakland, CA.
J Foot Ankle Surg. 2020 Mar-Apr;59(2):269-273. doi: 10.1053/j.jfas.2019.02.008.
Bisphosphonates (BP) are used to treat osteoporosis, although rare atypical femur fractures have occurred with long-term exposure, especially among Asians. Metatarsal fractures have also been reported with atypical femur fracture. We examined the epidemiology of metatarsal fractures among 48,390 females aged ≥50 years who initiated oral BP and were followed for a median 7.7 years, including 68 females who experienced an atypical femur fracture. Incident metatarsal fractures after BP initiation were identified by clinical diagnoses and validated by record review. The association of BP, clinical risk factors, race/ethnicity, and metatarsal fracture was examined by using Cox proportional hazard analyses. Among 1123 females with incident metatarsal fracture, 61.0% had an isolated fifth metatarsal fracture. The incidence of metatarsal fracture was 312 per 100,000 person-years of follow-up and was substantially lower for Asians. The adjusted relative rate for metatarsal fractures was 0.5 (95% confidence interval 0.4 to 0.6) for Asians compared with whites. Younger age, prior fracture, other risk factors, and current BP were associated with an increased relative rate of metatarsal fracture, but BP duration was not. Females with atypical femur fracture were not more likely to experience metatarsal fracture (2.9% versus 2.3%, p = .7), but only 68 females had an atypical fracture and stress fracture of the metatarsals was not examined. Except for age, the demographic profile for metatarsal fracture after initiating BP was similar to that for osteoporotic fracture, with Asians at a much lower risk. Although metatarsal fractures were not associated with BP duration or atypical femur fracture, the subset of metatarsal stress fractures was not specifically examined.
双膦酸盐 (BP) 用于治疗骨质疏松症,尽管长期暴露时会发生罕见的非典型股骨骨折,尤其是在亚洲人群中。也有报道称非典型股骨骨折伴跖骨骨折。我们研究了 48390 名年龄≥50 岁开始口服 BP 的女性中跖骨骨折的流行病学,中位随访时间为 7.7 年,其中 68 名女性发生了非典型股骨骨折。通过临床诊断确定 BP 起始后的骨折事件,并通过记录审查进行验证。通过 Cox 比例风险分析检查 BP、临床危险因素、种族/民族与跖骨骨折的关系。在 1123 名发生跖骨骨折的女性中,61.0%为孤立的第五跖骨骨折。跖骨骨折的发生率为每 100000 人年 312 例,亚洲人的发生率明显较低。与白人相比,亚洲人的跖骨骨折调整相对危险度为 0.5(95%置信区间 0.4 至 0.6)。年龄较小、既往骨折、其他危险因素和当前 BP 与跖骨骨折的相对危险度增加相关,但 BP 持续时间无此相关性。发生非典型股骨骨折的女性发生跖骨骨折的可能性并不更高(2.9%比 2.3%,p=0.7),但仅有 68 名女性发生非典型骨折,且未检查跖骨的应力性骨折。除年龄外,开始使用 BP 后跖骨骨折的人口统计学特征与骨质疏松性骨折相似,亚洲人骨折风险低得多。尽管 BP 持续时间或非典型股骨骨折与跖骨骨折无关,但并未专门检查跖骨的应力性骨折亚组。